Cost-Consequence Analysis Evaluating the Use of Botulinum Neurotoxin-A in Patients with Detrusor Overactivity Based on Clinical Outcomes Observed at a Single UK Centre-Reference-Cited by-同舟云学术

Cost-Consequence Analysis Evaluating the Use of Botulinum Neurotoxin-A in Patients with Detrusor Overactivity Based on Clinical Outcomes Observed at a Single UK Centre

Published:2006-03 Issue:3 Volume:49 Page:519-527
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Kalsi Vinay,Popat Roshni B.,Apostolidis Apostolos,Kavia Rajesh,Odeyemi Isaac A.O.,Dakin Helen A.,Warner Juliet,Elneil Soheir,Fowler Clare J.,Dasgupta Prokar

Publisher

Elsevier BV

Subject

Urology

Reference26 articles.

1. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study;Giannantoni;J Urol,2004

2. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study;Schurch;J Urol,2005

3. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity;Reitz;Eur Urol,2004

4. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra;Smith;Urology,2005

5. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence;Grosse;Eur Urol,2005

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost and Insurance Issues in Botulinum Toxin Therapy;Botulinum Toxin Treatment;2024

2. Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders;Pharmacological Reviews;2023-03-14

3. Functional Polymorphism in the ADRB3 Gene, Encoding the Beta-3 Adrenergic Receptor, and Response to Intra-Detrusor Injection of Botulinum Toxin-A in Women with Overactive Bladder;Journal of Clinical Medicine;2022-12-17

4. Health Care Economic Burden of Treatment and Rehabilitation for Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review;Journal of Urology;2022-10

5. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder;Urology;2021-03